Buy & Sell Soleno Therapeutics Inc (SLNO) – Soleno Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $2.76BMarket Cap
- HealthSector
- -26.73%3M Drawdown
- $2.56BEnterprise Value
- -Dividend Yield
- 15 daysTypical Hold Time
Soleno Therapeutics Inc (SLNO) is currently valued at a market capitalization of $2.76B, with an enterprise value of $2.56B. Over the past 52 weeks, Soleno Therapeutics Inc has traded between a low of $30.05 and a high of $88.49, highlighting its annual price range. Over the past three months, Soleno Therapeutics Inc has recorded a drawdown of -26.73%, reflecting recent price volatility. On average, investors hold Soleno Therapeutics Inc for approximately 15 days, indicating typical investor behavior on the platform.
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases. The company's lead product candidate, DCCR (Diazoxide Choline Extended-Release), is currently in late-stage clinical trials for the treatment of Prader-Willi Syndrome (PWS), a complex genetic disorder that causes a constant feeling of hunger (hyperphagia). Soleno is committed to addressing the significant unmet medical need in the PWS community.
Most Recent News
BlackRock plans up to $10B investment in SpaceX's historic $1.75T IPO debut.
BlackRock is reportedly considering investing between $5 billion and $10 billion in SpaceX's upcoming IPO, which aims to raise $75 billion at a valuation of about $1.75 trillion. This could become the largest IPO in history, with SpaceX planning to l...
ELEKTROS advances lithium mining and EV charging tech amid rising global demand for electrification.
ELEKTROS Inc. is accelerating its lithium mining projects in Sierra Leone and advancing patented EV charging technology to capitalize on growing global demand for electric vehicles and battery infrastructure. The company highlights the strategic impo...
Five dividend stocks offer 11.6%-20% annual returns with nearly 7% yields through 2030, says analyst.
Analyst Mark Bern highlights five dividend stocks—HTO, ES, SNY, NLY, and AMCR—that are trading below their estimated fair value and have strong balance sheets with good growth potential. These stocks are projected to deliver double-digit average annu...
